» Articles » PMID: 33360025

Cytokine Storm Induced by SARS-CoV-2 Infection: The Spectrum of Its Neurological Manifestations

Overview
Journal Cytokine
Date 2020 Dec 28
PMID 33360025
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The new coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can trigger a hyperinflammatory state characterized by elevated cytokine levels known as hypercytokinemia or cytokine storm, observed most often in severe patients. Though COVID-19 is known to be a primarily respiratory disease, neurological complications affecting both the central and peripheral nervous systems have also been reported. This review discusses potential routes of SARS-CoV-2 neuroinvasion and pathogenesis, summarizes reported neurological sequelae of COVID-19, and examines how aberrant cytokine levels may precipitate these complications. Clarification of the pathogenic mechanisms of SARS-CoV-2 is needed to encourage prompt diagnosis and optimized care. In particular, identifying the presence of cytokine storm in patients with neurological COVID-19 manifestations will facilitate avenues for treatment. Future investigations into aberrant cytokine levels in COVID-19 patients with neurological symptoms as well as the efficacy of cytokine storm-targeting treatments will be critical in elucidating the pathogenic mechanisms and effective treatments of COVID-19.

Citing Articles

Case report: Rare Guillain-Barré syndrome variants and mild encephalitis/encephalopathy with a reversible splenial lesion as the para-infectious manifestations of SARS-CoV-2 infection.

Si W, Li Y, Du G Front Immunol. 2024; 15:1458231.

PMID: 39430766 PMC: 11486701. DOI: 10.3389/fimmu.2024.1458231.


Neurological complications of SARS-CoV-2 infection among solid organ transplanted patients: does immunosuppression matter?.

Avorio F, Russelli G, Panarello G, Alduino R, Conaldi P, Lo Re V Front Neurol. 2024; 15:1393104.

PMID: 39026584 PMC: 11254845. DOI: 10.3389/fneur.2024.1393104.


Induction of Superior Systemic and Mucosal Protective Immunity to SARS-CoV-2 by Nasal Administration of a VSV-ΔG-Spike Vaccine.

Yahalom-Ronen Y, Melamed S, Politi B, Erez N, Tamir H, Bar-On L Vaccines (Basel). 2024; 12(5).

PMID: 38793742 PMC: 11125831. DOI: 10.3390/vaccines12050491.


The critical impacts of cytokine storms in respiratory disorders.

Riyaz Tramboo S, Elkhalifa A, Quibtiya S, Ali S, Shah N, Taifa S Heliyon. 2024; 10(9):e29769.

PMID: 38694122 PMC: 11058722. DOI: 10.1016/j.heliyon.2024.e29769.


Identification of predictive patient characteristics for assessing the probability of COVID-19 in-hospital mortality.

Rajwa B, Naved M, Adibuzzaman M, Grama A, Khan B, Dundar M PLOS Digit Health. 2024; 3(4):e0000327.

PMID: 38652722 PMC: 11037536. DOI: 10.1371/journal.pdig.0000327.


References
1.
Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F . Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020; 146(1):119-127.e4. PMC: 7189843. DOI: 10.1016/j.jaci.2020.04.027. View

2.
Mahmud-Al-Rafat A, Haque Asim M, Taylor-Robinson A, Majumder A, Muktadir A, Muktadir H . A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases. Cytokine. 2020; 136:155228. PMC: 7428755. DOI: 10.1016/j.cyto.2020.155228. View

3.
Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, Begni B . Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab. 1999; 19(9):1004-9. DOI: 10.1097/00004647-199909000-00008. View

4.
Xia H, Lazartigues E . Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem. 2008; 107(6):1482-94. PMC: 2667944. DOI: 10.1111/j.1471-4159.2008.05723.x. View

5.
Hasegawa S, Matsushige T, Inoue H, Shirabe K, Fukano R, Ichiyama T . Serum and cerebrospinal fluid cytokine profile of patients with 2009 pandemic H1N1 influenza virus-associated encephalopathy. Cytokine. 2011; 54(2):167-72. DOI: 10.1016/j.cyto.2011.01.006. View